Regulatory Requirements for Registration of Generic Drug Products in Japan

Authors

  • Sudi Daniel Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, NITTE University, Mangalore, Karnataka, India
  • Mudit Dixit Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangalore, Karnataka, India

DOI:

https://doi.org/10.37591/tdd.v2i2.277

Abstract

Drug registration is a procedure of expertise of the pharmaceutical product quality, efficacy and safety by regulatory authority. The emergence of various formats has enabled the manufacturers of drugs to easily gain access into various markets and thus, was able to place their products in the market. The choice of Japan as one of the destinations for the market of the Drug products ensures the manufacturer a good market value. Japan is considered as one of the strongest and promised markets for the registration of the drugs. Of late, generic drugs are holding major stake in the pharmaceutical market and are gaining more and more confidence in the usage. Majority of medicines in Japan are generic drugs which are considered as value for the money and affordable. Generic drugs are pharmaceutical products that are approved for manufacture, and are prescribed as drugs with equivalent therapeutic effects to those of the original drugs. The quality, safety and efficacy of the generic drugs do not differ from those of the original drugs. In Japan, the expiry of drug patents has given rise to many generic products. The reduction in price provides its availability for the public in a cheaper price. Pharmaceuticals and Medical Devices Agency (PMDA) carries out the registration process of drug products in Japan. The registration process mainly includes specification, accelerated stability studies and bioequivalence rather than complete tests required for an innovator drug.

 

Keywords: PMDA, MHLW, generics, CTD, bioequivalence


Cite this Article

Daniel Sudi, Dixit Mudit. Regulatory requirements for registration of generic drug products in Japan. Trends in Drug Delivery. 2015; 2(2): 19–27p

Downloads

Published

2019-02-21

Issue

Vol. 2 No. 2 (2015)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.